Patheon and Swiftwater will combine resources to provide regulatory consulting services to clients.
Swiftwater Group can assist Patheon clients as they navigate through the regulatory process, by providing expertise in regulatory strategy for CMC, non-clinical, and clinical development and by assisting clients to prepare and manage their regulatory submissions.
Wes Wheeler, CEO and president of Patheon, said: “This new partnership allows Patheon to further expand its services portfolio. We have found that many of our clients benefit from strategic and tactical assistance with their new drug application filings, 505(b) 2 filings, bioequivalence requirements, technical transfers and pediatric line extension strategies. We can now offer a complete service to our clients.”